Researchers at the UConn Center of Excellence in Vaccine Research have made a breakthrough in vaccine development for a common and difficult to treat pneumonia-causing pathogen
For Mycoplasma pneumoniae, vaccine development has been stalled since the 1960s due to a phenomenon called a vaccine-enhanced disease or vaccine-induced disease exacerbation. A vaccine for this type of community-acquired pneumonia has been long sought since the illness can pose problems for closed community settings.